SCHEMBL23728786

SCHEMBL23728786

Cc1sc(NC(=O)[C@H](N)CC(=O)O)c(C(=O)c2ccc(Cl)cc2)c1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.55
▸ MAPT P10636 7/20 0.55
▸ LMNA P02545 4/20 0.55
▸ HPGD P15428 7/20 0.53
▸ MAPK1 P28482 2/20 0.53
▸ PLA2G1B P04054 1/20 0.53
▸ ATG4B Q9Y4P1 1/20 0.53
▸ NPSR1 Q6W5P4 3/20 0.52
▸ HTT P42858 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ CYP1A2 P05177 2/20 0.44
▸ CYP2C9 P11712 2/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ GRIN2C Q14957 2/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15281425 1.00 ALDH1A1 (0.55) ALDH1A1MAPTLMNAHPGDMAPK1
SCHEMBL19136021 1.00 ALDH1A1 (0.55) ALDH1A1MAPTLMNAHPGDMAPK1
SCHEMBL18551518 0.90 ALDH1A1 (0.52) ALDH1A1MAPTLMNAHPGDMAPK1
SCHEMBL30411459 0.89 ALDH1A1 (0.53) ALDH1A1MAPTLMNAHPGDMAPK1
SCHEMBL17165584 0.88 ALDH1A1 (0.57) ALDH1A1MAPTLMNAHPGDMAPK1
SCHEMBL17165585 0.88 ALDH1A1 (0.57) ALDH1A1MAPTLMNAHPGDMAPK1
SCHEMBL31498681 0.88 ALDH1A1 (0.57) ALDH1A1MAPTLMNAHPGDMAPK1
SCHEMBL31498738 0.85 ALDH1A1 (0.54) ALDH1A1MAPTLMNAHPGDMAPK1
SCHEMBL872772 0.85 BRD4 (0.49) ALDH1A1MAPTLMNAHPGDMAPK1
SCHEMBL872773 0.85 BRD4 (0.49) ALDH1A1MAPTLMNAHPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240050576-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2024-02-15 — — US disclosed
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-05-18 — — US disclosed
EP-4100404-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. (US) 2022-12-14 — — EP disclosed
WO-2021158707-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. (US) 2021-08-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE DMPK, DTYMK, MYCBP ALDH1A1 4368/4885MAPT 946/4885LMNA 136/4885
US-20240050576-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE ZFX, GRN, F13B ALDH1A1 4800/4885MAPT 3053/4885LMNA 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback